| |
Curing HBV, New Drugs
|
| |
| |
"in order to effectively clear an HBV infection and produce full remission, the viral cccDNA intermediates need to be destroyed"
AASLD: Curing HBV....attacking cccDNA "Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease" - (01/12/15)
AASLD: HBV at AASLD - (01/13/15)
A new priority for the ANRS: "HBV Cure" - (01/05/15)
"........any CURE of chronic hepatitis B will require elimination of cccDNA......cccDNA - HBV's largely unexplored persistence reservoir....." Jurgen Beck's talk see slide set in link above
AASLD: Phase 1a Safety and Pharmacokinetics of NVR 3-778, a Potential First-In-Class HBV Core Inhibitor - (01/16/15)
Targeted In Vivo Delivery of siRNA and an Endosome-Releasing Agent to Hepatocytes - (01/13/15)
Arrowhead Files IND for RNAi Therapeutic ARC-520 to Begin Phase 2b Multiple-Dose Studies in Chronic Hepatitis B Patients - (01/13/15)
AASLD: Phase II, dose ranging study of ARC-520, a siRNA-based therapeutic, in patients with chronic hepatitis B virus infection - (01/13/15)
AASLD: Phase II, dose ranging study of ARC-520, a siRNA-based therapeutic, in patients with chronic hepatitis B virus infection - (01/13/15)
AASLD: Curing HBV....attacking cccDNA "Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease" - (01/12/15)
AASLD: Phase 1a Safety and Pharmacokinetics of NVR 3-778, a Potential First-In-Class HBV Core Inhibitor - (01/12/15)
AASLD: Novira Therapeutics Announces Presentation of Phase 1a - Safety and Pharmacokinetic Data for NVR 3-778 - (01/12/15)
AASLD: The Antiviral Response to the Toll-Like Receptor 7 Agonist GS-9620 in Preclinical Models of Chronic Hepatitis B is Associated With an Intrahepatic Cytotoxic T Cell Transcriptional Signature - (01/12/15)
AASLD: Cytokines Induced by a Toll-Like Receptor 7 Agonist Potently Inhibit HBV RNA, DNA, and Antigen Levels in Primary Human Hepatocytes - (01/12/15)
GS-9620, an Oral Agonist of Toll-Like Receptor-7, Induces Prolonged Suppression of Hepatitis B Virus in Chronically Infected Chimpanzees - (01/05/15)
Targeting Innate Immunity [GS-9620]: A New Step in the Development of Combination Therapy for Chronic Hepatitis B - (01/05/15)
More Hep B Articles...
|
|
| |
| |
|
|
|
